GB2544468A — Liquid formulation
Assigned to JAYTEE BIOSCIENCES Ltd · Expires 2017-05-24 · 9y expired
What this patent protects
The present invention relates to a liquid formulation comprising cannabidiol, a stabiliser and a liquid carrier. The liquid carrier includes propylene glycol; and the stabiliser comprises a head portion and a tail portion, wherein the head portion includes one or more reducing mo…
USPTO Abstract
The present invention relates to a liquid formulation comprising cannabidiol, a stabiliser and a liquid carrier. The liquid carrier includes propylene glycol; and the stabiliser comprises a head portion and a tail portion, wherein the head portion includes one or more reducing moieties and the tail portion comprises a C3-C20 straight or branched aliphatic chain. Preferably the stabiliser is butylated hydroxyanisole (BHA) or 6-O-palmitoyl-L-ascorbic acid (also known as 6-O-AP or ascorbyl palmitate). The formulation may further comprise one or more glyceride compounds from a plant source, nicotine, a flavouring agent and/or a scent agent. Preferably the formulation is substantially free from tetrahydrocannabinol (THC). Also claimed is an e-cigarette liquid comprising the liquid formulation.
Drugs covered by this patent
- Marinol (DRONABINOL) · Wellhouse Pharma
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.